Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News CNBX Pharmaceuticals Inc (PK) CNBX

Healthcare Biotechnology Cannabis
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various... see more

Recent & Breaking News (PINL:CNBX)

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma

PR Newswire November 8, 2022

CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy

PR Newswire October 18, 2022

CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

PR Newswire October 13, 2022

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate

PR Newswire September 29, 2022

CNBX Pharmaceuticals Announces New Patent Granted in Australia

PR Newswire September 28, 2022

CNBX Pharmaceuticals Release a New Corporate Presentation

PR Newswire May 31, 2022

CNBX Pharmaceuticals Granted Patent in Hong Kong

PR Newswire May 5, 2022

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals

PR Newswire March 28, 2022

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

PR Newswire November 4, 2021

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago

PR Newswire October 26, 2021

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

PR Newswire October 25, 2021

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

PR Newswire October 21, 2021

CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas

PR Newswire October 20, 2021

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

PR Newswire October 19, 2021

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

PR Newswire October 18, 2021

CEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference

PR Newswire October 14, 2021

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

PR Newswire September 30, 2021

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

PR Newswire September 22, 2021

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

PR Newswire September 21, 2021

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

PR Newswire September 13, 2021

Podcasts